TX-COGNITIVE-SPACE
8.12.2021 04:42:05 CET | Business Wire | Press release
Cognitive Space announced the highlights of a very successful year in its mission to dramatically improve the way we monitor the Earth for economic, environmental, and national security understanding. The company helps organizations fly their satellites with new tools for New Space - providing satellite operators and space infrastructure companies with sophisticated SaaS services for optimizing revenue and performance yield, forecasting future capacity, and orchestrating collection management as satellite constellations grow and scale.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211207006237/en/
“The New Space economy is attracting massive investment and is growing exponentially. Space will be filled with thousands of new commercial satellites,” said Scott Herman, CEO of Cognitive Space. “But building out the required ground architecture is a major hurdle for New Space companies and usually represents a significant monetary investment, a multi-year time commitment, and major execution risk as they build their business. Cognitive Space provides a blueprint and an operational capability that de-risks and accelerates their buildout schedule, controls costs, and then optimizes their ongoing operations to power their business vision.”
2021 Highlights for Cognitive Space:
$5.5M in Investment Capital raised – Cognitive Space started the year with a $1.5M “pre-seed” raise, followed in November with the closing of a $4M Series Seed led by Grit Ventures of Menlo Park. Additional investors include Argon Ventures, Techstars, UltraTech Capital Partners, Cultivation Capital, Glasswing Ventures, Gutbrain Ventures, PBJ Capital, SpaceFund, and Deep Ventures. Outside counsel for the transaction were Covington and Burling LLP. As a result of this 2021 fundraising effort, Cognitive Space enters 2022 with $5.5M in funds ready to apply towards commercial product development and company growth.
“Billions of investment dollars are flowing into the New Space economy. There is an unmet imperative for cost-effective, scalable, and business-savvy constellation operations,” commented Jennifer Gill Roberts, Managing Partner at Grit Ventures. “We believe Cognitive Space's AI-driven approach to maximizing constellation revenue and performance yield gives their customers a significant competitive advantage in this emerging market for Space-based services.”
New and expanded US Government contracts – Cognitive Space continued its work with several US Government agencies, including the US Space Force, the Air Force Research Lab (AFRL), the National Geospatial Intelligence Agency (NGA), and other members of the national security community. In these engagements Cognitive Space focused on concept development and rapid prototyping for topics such as orchestrated collection management, hybrid space architecture, and global monitoring. Of particular note, Cognitive Space was selected as a winner of the Space Force Pitch Day competition, resulting in a $1.7M contract for exploring new approaches to satellite operations using Artificial Intelligence.
Cognitive Space also supported several US Government exercises, including RIMPAC, Northern Edge, and Joint Warrior. The company orchestrated collection opportunities across multiple commercial and government suppliers of satellite remote sensing. Cognitive Space provided the US Government with insight into the emerging wave of commercial remote sensing capabilities, helping them understand the impact of these capabilities on future operations, tradecraft, tools, and procurement methods.
Commercial Sales Traction – This summer, Cognitive Space introduced its SaaS-based platform for autonomous and dynamic satellite operations to a growing set of commercial satellite operators and space infrastructure companies. The platform revolutionizes satellite operations with the power of artificial intelligence for mission management, collections planning, and communications link coordination. The suite is available in versions tailored for startups, growth, and enterprise-class customers in the New Space domain.
Strong Revenue growth – Cognitive Space continues to dramatically increase its year-over-year revenue with new contracts, solid bookings, and a dense opportunity pipeline going into 2022.
Accelerator Wins – Cognitive Space was competitively selected for several startup accelerators, including the Amazon Web Services (AWS) Seraphim Space Accelerator and the NGA Startup Accelerator. As one of 10 companies chosen by AWS out of a field of approximately 200 startups, Cognitive Space received $100,000 in cloud infrastructure credits, AWS Cloud training and support, mentorship, and additional business development resources including opportunities to speak with space-savvy venture investors. With the NGA Accelerator, Cognitive Space has been working with government analysts on a pilot project exploring the role of future commercial satellite capabilities for facility monitoring and pattern-of-life analytics in real-world scenarios.
Building the best team in AI-driven Satellite Operations – Cognitive Space continues to recruit aggressively for an expanding team of AI/ML scientists and mathematicians, satellite and aerospace engineers, full-stack and frontend/backend developers, system architects, and Cloud DevOps engineers. In 2021, the company also made strategic additions to the executive team by recruiting senior industry veterans Scott Herman (as CEO) and Hanna Steplewska (as VP, Business Development & Operations). Scott and Hanna bring deep experience in Space Operations, Satellite Remote Sensing, Geospatial Analytics, and National Security and a comprehensive understanding of the New Space ecosystem.
About Cognitive Space
More information about Cognitive Space can be found at http://www.cognitivespace.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211207006237/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom